Search the Newsreel

AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed'

AstraZeneca's stock fell sharply after reports emerged of potential merger talks with Bristol Myers Squibb, a deal that could create a $400 billion pharmaceutical giant. Analysts expressed bewilderment over the strategic rationale, given AstraZeneca's strong growth and pipeline, while Bristol Myers faces upcoming patent …

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb are reportedly in discussions for a merger that could create a pharmaceutical giant valued at approximately $400 billion. The talks have been ongoing for several months and, if successful, would make AstraZeneca the world’s fourth-largest drugmaker by market capitalization. …

AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AstraZeneca has reportedly held talks with Bristol Myers Squibb regarding a potential merger that could create a pharmaceutical giant valued at nearly $400 billion. The Financial Times reported on Sunday that discussions have occurred in recent months, though a deal could still be delayed …

AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE)

AstraZeneca (AZN) and Bristol Myers Squibb (BMY) reportedly held preliminary discussions regarding a potential merger. This combination, if it materializes, would result in one of the world's largest pharmaceutical companies. The news was reported by the Financial Times.

AstraZeneca, Bristol Myers Squibb Held Talks for Tie-Up, FT Says

AstraZeneca Plc and Bristol Myers Squibb Co. reportedly held discussions about a potential merger to combine the two pharmaceutical companies. The Financial Times, citing familiar sources, stated that these talks occurred in recent months, though the specifics of the deal structure were not detailed …

Bristol-Myers Squibb Company supera las previsiones de los analistas: descubre cuáles son las previsiones de consenso para este año

Lazard Asset Management LLC Purchases 64,018 Shares of Myers Industries, Inc. $MYE

Lazard Asset Management LLC significantly increased its stake in Myers Industries, Inc. (NYSE:MYE) during the first quarter, purchasing an additional 64,018 shares to hold a total of 155,766 shares valued at approximately $3.3 million. This comes as Myers Industries reported strong second-quarter results, exceeding …

Bristol-Myers Squibb Company Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

KeyBanc Maintains Myers Industries(MYE.US) With Buy Rating, Maintains Target Price $37

KeyBanc has reaffirmed its Buy rating for Myers Industries (MYE.US) and maintained its target price of $37. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Access Investment Management LLC Has $1.13 Million Stock Position in Myers Industries, Inc. $MYE

Access Investment Management LLC decreased its stake in Myers Industries (NYSE:MYE) by 64.4% in the first quarter, now owning 53,145 shares valued at $1.13 million. Despite this, other institutional investors like Bank of America Corp DE and Arrowstreet Capital Limited Partnership increased their holdings. …

Myers Industries, Inc. Revenue Breakdown – FWB:MJF

Myers Industries, Inc. (FWB: MJF) generated 703.05 million EUR in revenue last year. Its top-performing segment, Material Handling, contributed 529.71 million EUR. The United States was the largest regional contributor, accounting for 654.95 million EUR of the company's revenue.

Bristol-Myers Squibb Company : Consenso de Precios Objetivo y Recomendaciones de los Analistas | BMY | US1101221083

Allspring Global discloses 3.7% Myers Industries (MYE) ownership on Schedule 13G/A

Allspring Global Investments Holdings, LLC has filed an Amendment No. 3 to Schedule 13G/A, reporting beneficial ownership of 1,400,451 shares of Myers Industries, Inc. common stock, which represents 3.7% of the class. Allspring Global maintains sole voting power over 1,399,636 shares and sole dispositive …

Myers Industries Posts ‘Outstanding’ Revenue Growth in Q2 Report

Myers Industries Inc. announced outstanding revenue growth and expanded profitability for its second quarter ended June 30, 2026. The company reported a 13% increase in net sales, with significant growth in Infrastructure and Food & Beverage segments, driven by strategic initiatives and operational improvements. …

Scepter Launches Military Ammunition Container Production

Myers Industries' Scepter business has commenced production of military ammunition containers in Europe through Scepter International Poland. This strategic expansion strengthens the company's defense manufacturing capabilities, particularly for NATO and allied nations, by providing lightweight, reusable polymer packaging that replaces traditional metal and wood …

Guggenheim eleva el precio objetivo de Bristol-Myers Squibb a 75 dólares

Bristol Myers Squibb (BMY) Earnings Beat And Higher Outlook Put Valuation Back In Focus

Myers bets on military packaging for a plastics growth platform

Myers Industries Inc. is seeing rapid growth in its Scepter business as militaries worldwide are replacing traditional wooden and steel ammunition boxes with plastic alternatives. This shift positions military packaging as a significant growth platform for the company's plastics division. The company's Scepter business …

Bristol Myers Squibb (BMY) Stock Shrugs Off Profit Surge And Patent Risk

Myers Industries Inc (MYE) (Q2 2026) Earnings Call Highlights: Revenue Growth Amidst Persistent ...

Myers Industries Inc (MYE) reported strong revenue growth in Q2 2026 driven by increased demand and operational efficiencies, with management expressing confidence in full-year guidance. However, the company faced challenges including persistent supply chain disruptions, higher raw material costs, labor shortages, softer demand in …

Bristol-Myers, Merck win FDA review for Reblozyl label expansion

The FDA has accepted Bristol-Myers Squibb's marketing application for an expanded U.S. label for its anemia therapy, Reblozyl. This drug was developed in partnership with Merck. The announcement was made during Bristol-Myers Squibb's Q2 2026 financial report.

Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views

U.S. stocks saw broad gains, with the Dow up 0.40%, NASDAQ surging 2.08%, and the S&P 500 rising 0.89%. Bristol-Myers Squibb reported better-than-expected Q2 earnings and raised its FY2026 guidance, while gold prices surged 3%. Several companies, including Columbus McKinnon, Marketaxess Holdings, and Xerox …

Earnings call transcript: Myers Industries tops Q2 2026 profit estimates

Myers Industries reported adjusted earnings of $0.53 per share for Q2 2026, significantly exceeding Wall Street estimates of $0.32, driven by stronger margins and cost controls, despite revenue falling short of forecasts. The company's Focused Transformation strategy, emphasizing higher-margin products and operational improvements, contributed …

Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat

Bristol Myers Squibb has once again delayed the phase 3 data readout for its Alzheimer's disease psychosis drug, Cobenfy, moving the expected arrival of data to early 2027 due to slower patient enrollment and relapse event accrual. Despite this setback and a muted launch …

Earnings Flash (MYE) Myers Industries Inc. Reports Q2 Revenue $179.2M

Myers Industries Inc. (MYE) announced its Q2 revenue reached $179.2 million. The report provides a snapshot of the company's financial performance for the quarter.

Bristol Myers Squibb erhöht die Prognose für 2026 nach besser als erwarteten Ergebnissen im zweiten Quartal.

Bristol Myers Squibb raises 2026 forecast after Q2 earnings beat

Bristol Myers Squibb has increased its full-year revenue and earnings forecast for 2026 following better-than-expected second-quarter results. Strong sales of its blood thinner Eliquis, along with newer drugs like Camzyos and Reblozyl, drove revenue to $12.97 billion, surpassing analyst estimates. The company now expects …

Myers Industries, Inc. Amends and Extends $250 Million Revolving Credit Facility and Establishes $250 Million Term Loan

Myers Industries, Inc. has amended and extended its existing loan agreement, securing a $250 million revolving credit facility and establishing a new $250 million term loan. The amendment extends the maturity date of the revolving credit facility, refinances existing term loans, and adjusts leverage …

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

Bristol Myers Squibb reported its second-quarter 2026 financial results, which can be viewed on the company's Investor Relations website. The biopharmaceutical company hosted a conference call and live audio webcast for analysts and investors to discuss these results. A replay of the webcast will …

Bristol-Myers stock gains after Q2 2026 beat (BMY:NYSE)

Bristol-Myers Squibb (BMY) raised its full-year outlook after reporting better-than-expected Q2 2026 financials, driven by strong sales of its cancer therapies. The company reported approximately $13.0B in revenue, a ~6% YoY growth. The updated guidance for full-year revenue is $49.0B–$50.0B and adjusted EPS is …

Bristol Myers Raises Guidance After Record-Breaking Sales

Bristol Myers Squibb Co. increased its sales and profit outlook for 2026 following better-than-expected second-quarter demand for its drugs, particularly newer treatments for heart conditions and cancer. The company now expects full-year sales between $49 billion and $50 billion, up from an earlier forecast, …

Bristol-Myers Squibb superaron 0.43$ las previsiones de BPA en el segundo trimestre del año

BRISTOL-MYERS SQUIBB ($BMY) Releases Q2 2026 Earnings

Myers: Q2 Earnings Snapshot

This article is a placeholder for a Q2 earnings snapshot for Myers. It currently contains no detailed financial information, suggesting the content is missing or has not yet been fully published.

Myers Industries Secures $250M Term Loan, Extends $250M Revolver in Five-Year Amended Facility

Myers Industries has amended its credit agreement, securing a new $250 million term loan and extending its existing $250 million revolving facility for five years. This amendment also lowers interest margins, updates leverage covenants, and removes the LIBOR adjustment. The proceeds will be used …

MYERS INDUSTRIES INC Q2 2026: Revenue $179.2M, EPS $0.53— 10-Q Summary

MYERS INDUSTRIES INC reported strong second-quarter 2026 results, with revenue reaching $179.2 million and diluted earnings per share at $0.53, indicating significant year-over-year growth. The company saw a 9.8% increase in revenue and more than double its net income and EPS compared to the …